Top

Published in:

01-08-2014 | Original Article

Screening for Barrett’s Esophagus: Results from a Population-Based Survey

Authors: Milli Gupta, Timothy J. Beebe, Kelly T. Dunagan, Cathy D. Schleck, Alan R. Zinsmeister, Nicholas J. Talley, G. Richard Locke III, Prasad G. Iyer

Published in: Digestive Diseases and Sciences | Issue 8/2014

Abstract

Background

Screening for Barrett’s esophagus (BE) and adenocarcinoma (EAC) is controversial, but interest remains in finding the optimal method. Attitudes on screening within the community are unknown. We aimed to assess these attitudes via a survey.

Study

A mixed-mode survey was conducted in adults >50 years to assess awareness regarding BE, willingness to participate in screening, and preferences regarding method of screening. Methods evaluated were sedated endoscopy (sEGD), unsedated transnasal endoscopy (uTNE) and video capsule (VCE).

Results

A total of 136 from 413 (33 %) adults responded [47 % males, mean (SD) age 63 (10.2) years], and 26 % of responders knew of BE at baseline. After reading the information on BE, 72 % were interested in screening. A history of undergoing screening tests and GI symptoms were predictive of interest. Unsedated techniques were preferred by 64 % (VCE: 56 % and uTNE: 8 %) versus sEGD (36 %).

Conclusions

The majority of adults were willing to undergo screening for BE/EAC, with a preference for unsedated techniques.

Available only for authorised users

Spechler SJ. Screening and surveillance for Barrett’s esophagus-an unresolved dilemma. Nat Clin Pract Gastroenterol Hepatol. 2007;4:470–471.PubMedCrossRef

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.PubMedCrossRef

Wani S, Falk G, Hall M, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220–227; quiz e226.

Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology. 1990;99:918–922.PubMed

Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett’s esophagus: a population-based study. Am J Gastroenterol. 2011;106:1447–1455.PubMedCentralPubMedCrossRef

Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–1831.PubMedCrossRef

Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008;103:788–797.PubMedCrossRef

Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633–640.PubMedCrossRef

Dellon ES, Shaheen NJ. Does screening for Barrett’s esophagus and adenocarcinoma of the esophagus prolong survival? J Clin Oncol. 2005;23:4478–4482.PubMedCrossRef

10.

Chang JY, Talley NJ, Locke GR 3rd, et al. Population screening for Barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc. 2011;86:1174–1180.PubMedCentralPubMedCrossRef

11.

Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:e18–e52; quiz e13.

12.

Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Health-related quality of life in patients with Barrett’s esophagus: a systematic review. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2009;7:613–623.

13.

Kruijshaar ME, Kerkhof M, Siersema PD, Steyerberg EW, Homs MY, Essink-Bot ML. The burden of upper gastrointestinal endoscopy in patients with Barrett’s esophagus. Endoscopy. 2006;38:873–878.PubMedCrossRef

14.

Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett’s adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg. 2002;6:29–35; discussion 36.

15.

Incarbone R, Bonavina L, Saino G, Bona D, Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett’s esophagus. Surg Endosc. 2002;16:263–266.PubMedCrossRef

16.

Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett’s esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg. 1994;108:813–821; discussion 821–822.

17.

van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett’s oesophagus on pathological stage and clinical outcome of Barrett’s carcinoma. Gut. 1998;43:216–222.PubMedCentralPubMedCrossRef

18.

Kadri SR, Lao-Sirieix P, O’Donovan M, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ. 2010;341:c4372.PubMedCentralPubMedCrossRef

19.

Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:e942.

20.

Kadri S, Lao-Sirieix P, Fitzgerald RC. Developing a nonendoscopic screening test for Barrett’s esophagus. Biomark Med. 2011;5:397–404.PubMedCrossRef

21.

Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106:254–260.PubMedCentralPubMedCrossRef

22.

Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology. 2013;144:e66.CrossRef

23.

Saeian K, Staff DM, Vasilopoulos S. Unsedated transnasal endoscopy accurately detects Barrett’s metaplasia and dysplasia. Gastrointest Endosc. 2002;56:472–478.PubMedCrossRef

24.

Saeian K, Staff D, Knox J, et al. Unsedated transnasal endoscopy: a new technique for accurately detecting and grading esophageal varices in cirrhotic patients. Am J Gastroenterol. 2002;97:2246–2249.PubMedCrossRef

25.

Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett’s esophagus: a randomized and blinded comparison. Am J Gastroenterol. 2006;101:2693–2703.PubMedCrossRef

26.

Osawa H, Yamamoto H, Yamada N, et al. Diagnosis of endoscopic Barrett’s esophagus by transnasal flexible spectral imaging color enhancement. J Gastroenterol. 2009;44:1125–1132.PubMedCrossRef

27.

Shariff MK, Bird-Lieberman EL, O’Donovan M, et al. Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett’s esophagus. Gastrointest Endosc. 2012;75:954–961.PubMedCrossRef

28.

Eliakim R, Sharma VK, Yassin K, et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol. 2005;39:572–578.PubMedCrossRef

29.

Gralnek IM, Adler SN, Yassin K, Koslowsky B, Metzger Y, Eliakim R. Detecting esophageal disease with second-generation capsule endoscopy: initial evaluation of the PillCam ESO 2. Endoscopy. 2008;40:275–279.PubMedCrossRef

30.

Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104:1533–1539.PubMedCrossRef

31.

Sharma P, Wani S, Rastogi A, et al. The diagnostic accuracy of esophageal capsule endoscopy in patients with gastroesophageal reflux disease and Barrett’s esophagus: a blinded, prospective study. Am J Gastroenterol. 2008;103:525–532.PubMedCrossRef

32.

Lin OS, Schembre DB, Mergener K, et al. Blinded comparison of esophageal capsule endoscopy versus conventional endoscopy for a diagnosis of Barrett’s esophagus in patients with chronic gastroesophageal reflux. Gastrointest Endosc. 2007;65:577–583.PubMedCrossRef

33.

Galmiche JP, Sacher-Huvelin S, Coron E, et al. Screening for esophagitis and Barrett’s esophagus with wireless esophageal capsule endoscopy: a multicenter prospective trial in patients with reflux symptoms. Am J Gastroenterol. 2008;103:538–545.PubMedCrossRef

34.

Chang JY, Talley NJ, Locke Iii GR, et al. Population screening for Barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc. 2011;86:1174–1180.PubMedCentralPubMedCrossRef

35.

Edwards PJ, Roberts I, Clarke MJ et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev. 2009;MR000008.

36.

Harewood GC, Yacavone RF, Locke GR 3rd, Wiersema MJ. Prospective comparison of endoscopy patient satisfaction surveys: e-mail versus standard mail versus telephone. Am J Gastroenterol. 2001;96:3312–3317.PubMedCrossRef

37.

Beebe TJ, Davern ME, McAlpine DD, Call KT, Rockwood TH. Increasing response rates in a survey of medicaid enrollees: the effect of a prepaid monetary incentive and mixed modes (mail and telephone). Med Care. 2005;43:411–414.PubMedCrossRef

38.

Beebe TJ, McAlpine DD, Ziegenfuss JY, Jenkins S, Haas L, Davern ME. Deployment of a mixed-mode data collection strategy does not reduce nonresponse bias in a general population health survey. Health Serv Res. 2012;47:1739–1754.PubMedCentralPubMedCrossRef

39.

Scott RG, Edwards JT, Fritschi L, Foster NM, Mendelson RM, Forbes GM. Community-based screening by colonoscopy or computed tomographic colonography in asymptomatic average-risk subjects. Am J Gastroenterol. 2004;99:1145–1151.PubMedCrossRef

40.

Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259–1268.PubMed

41.

Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county, minnesota. Gastroenterology. 1997;112:1448–1456.PubMedCrossRef

42.

Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291:71–78.PubMedCrossRef

43.

Choung RCLIG, Schleck C, Ziegenfuss JY, Beebe TJ, Zinsmeister AR, Talley NJ. A low response rate does not necessarily indicate non-response bias in gastroenterology survey research: a population-based study. J Public Health. 2013;21:87–95.

44.

45.

Dillard AJ, Couper MP, Zikmund-Fisher BJ. Perceived risk of cancer and patient reports of participation in decisions about screening: the decisions study. Med Decis Making. 2010;30:96S–105S.PubMedCrossRef

46.

Hoffman RM, Lewis CL, Pignone MP, et al. Decision-making processes for breast, colorectal, and prostate cancer screening: the decisions survey. Med Decis Making. 2010;30:53S–64S.PubMedCentralPubMedCrossRef

47.

Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol. 2001;33:306–309.PubMedCrossRef

48.

Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953–956.PubMedCrossRef

49.

Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J. 1982;126:46–48.PubMedCentralPubMed

50.

Singh S, Stein HJ, DeMeester TR, Hinder RA. Nonobstructive dysphagia in gastroesophageal reflux disease: a study with combined ambulatory ph and motility monitoring. Am J Gastroenterol. 1992;87:562–567.PubMed

51.

Blalock SJ, DeVellis BM, Afifi RA, Sandler RS. Risk perceptions and participation in colorectal cancer screening. Health Psychol. 1990;9:792–806.PubMedCrossRef

52.

McCaul KD, Branstetter AD, Schroeder DM, Glasgow RE. What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. Health Psychol. 1996;15:423–429.PubMedCrossRef

53.

54.

Ruffin MT, Gorenflo DW, Woodman B. Predictors of screening for breast, cervical, colorectal, and prostatic cancer among community-based primary care practices. J Am Board Fam Pract. 2000;13:1–10.PubMedCrossRef

55.

Hahn DL. The delivery of clinical preventive services: acute care intervention. J Fam Pract. 1999;48:785–789.PubMed

56.

Milne JS, Maule MM, Williamson J. Method of sampling in a study of older people with a comparison of respondents and non-respondents. Br J Prev Soc Med. 1971;25:37–41.PubMedCentralPubMed

57.

Heilbrun LK, Ross PD, Wasnich RD, Yano K, Vogel JM. Characteristics of respondents and nonrespondents in a prospective study of osteoporosis. J Clin Epidemiol. 1991;44:233–239.PubMedCrossRef

58.

Goldberg M, Chastang JF, Leclerc A, et al. Socioeconomic, demographic, occupational, and health factors associated with participation in a long-term epidemiologic survey: a prospective study of the French gazel cohort and its target population. Am J Epidemiol. 2001;154:373–384.PubMedCrossRef

59.

Atrostic BKBN, Burt G, Silberstein A. Nonresponse in U.S. Government household surveys: consistent measures, recent trends, and new insights. J Off Stat. 2001;17:18.

60.

Shaheen NJ, Dulai GS, Ascher B, Mitchell KL, Schmitz SM. Effect of a new diagnosis of Barrett’s esophagus on insurance status. Am J Gastroenterol. 2005;100:577–580.PubMedCrossRef

61.

Arguedas MR, Eloubeidi MA. Barrett’s oesophagus: a review of costs of the illness. Pharmacoeconomics. 2001;19:1003–1011.PubMedCrossRef

62.

Gross CP, Canto MI, Hixson J, Powe NR. Management of Barrett’s esophagus: a national study of practice patterns and their cost implications. Am J Gastroenterol. 1999;94:3440–3447.PubMedCrossRef

63.

Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186.PubMedCrossRef

Title: Screening for Barrett’s Esophagus: Results from a Population-Based Survey
Authors: Milli Gupta
Timothy J. Beebe
Kelly T. Dunagan
Cathy D. Schleck
Alan R. Zinsmeister
Nicholas J. Talley
G. Richard Locke III
Prasad G. Iyer
Publication date: 01-08-2014
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 8/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-014-3092-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Study

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Usefulness of Intraductal Ultrasonography in Icteric Patients with Highly Suspected Choledocholithiasis Showing Normal Endoscopic Retrograde Cholangiopancreatography

Nickel Free-Diet Enhances the Helicobacter pylori Eradication Rate: A Pilot Study

The 8th International Symposium on Cell/Tissue Injury and Cytoprotection/Organoprotection

Racial Disparities in the Proportion of Current, Unresolved Hepatitis C Virus Infections in the United States, 2003–2010

A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel

Does Rebamipide Prevent Gastric Mucosal Injury in Patients Taking Aspirin and Clopidogrel?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials